Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT05189977 Terminated - Clinical trials for Post-traumatic Stress Disorder (PTSD)

A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline

Start date: September 7, 2022
Phase: Phase 1
Study type: Interventional

A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline

NCT ID: NCT05177770 Terminated - Prostate Cancer Clinical Trials

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Start date: January 17, 2022
Phase: Phase 2
Study type: Interventional

This trial will look at the safety and preliminary efficacy of SRF617 in combination with etrumadenant and zimberelimab in patients with metastatic castration-resistant prostate cancer (mCRPC).

NCT ID: NCT05160168 Terminated - Neoplasms Clinical Trials

A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Start date: January 3, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will assess the safety, efficacy, and pharmacokinetics of THE-630 in participants with advanced gastrointestinal stromal tumors (GIST).

NCT ID: NCT05157360 Terminated - Sepsis Clinical Trials

HAT for the Treatment of Sepsis Associated With NASTI

Start date: September 10, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Evaluate the impact of HAT therapy versus placebo in the treatment of patients with an acute NSTI and sepsis.

NCT ID: NCT05153408 Terminated - Neoplasms Clinical Trials

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Start date: January 13, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1/2, open-label, first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of BLU-701 as monotherapy or in combination with either osimertinib or platinum-based chemotherapy in patients with EGFRm NSCLC.

NCT ID: NCT05140824 Terminated - Clinical trials for Systemic Lupus Erythematosus (SLE)

A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus

Start date: December 30, 2021
Phase: Phase 1
Study type: Interventional

A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Doses of TJ202 in Patients with Systemic Lupus Erythematosus

NCT ID: NCT05135650 Terminated - Clinical trials for Malignant Solid Neoplasm

Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study

Start date: January 25, 2022
Phase: Phase 1
Study type: Interventional

This phase I trial studies the process by which sotrovimab is absorbed, distributed, metabolized, and eliminated by the body (pharmacokinetics) in hematopoietic stem cell transplant recipients. Sotrovimab is a monoclonal antibody that may target and bind to a specific protein on SARS-CoV-2 and block its viral attachment and entry into human cells. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2 in hematopoietic stem cell transplant recipients.

NCT ID: NCT05131204 Terminated - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

ACCESS 2
Start date: October 6, 2022
Phase: Phase 3
Study type: Interventional

The primary objective of the study is: To evaluate the effect of pozelimab and cemdisiran combination therapy on hemolysis, as assessed by lactate dehydrogenase (LDH), after 36 weeks of treatment, in patients with PNH who switch from eculizumab or ravulizumab therapy versus patients who continue their eculizumab or ravulizumab therapy The secondary objectives of the study are to: - Evaluate the effect of pozelimab and cemdisiran combination treatment versus anti-C5 standard-of-care treatment (eculizumab or ravulizumab) on the following: - Transfusion requirements and transfusion parameters - Measures of hemolysis: LDH control, breakthrough hemolysis, and inhibition of CH50 - Hemoglobin levels - Fatigue as assessed by Clinical Outcome Assessments (COAs) - Health-related quality of life (HRQoL) as assessed by COAs - Safety and tolerability - To assess the concentrations of total pozelimab and either total eculizumab or total ravulizumab in serum and total cemdisiran and total C5 protein in plasma - To assess the immunogenicity of pozelimab and cemdisiran

NCT ID: NCT05129449 Terminated - Clinical trials for Cholangiopancreatography, Endoscopic Retrograde

A Clinical Study With the Medical Device PowerSpiral for Endoscopic Retrograde Cholangio-Pancreatography (ERCP)

SAMISEN-B
Start date: January 17, 2022
Phase:
Study type: Observational

The objective of the SAMISEN study phase B is to assess the performance and safety of diagnostic and therapeutic procedures with the Olympus Motorized Spiral Enteroscope (PowerSpiral) in subjects with surgically altered gastrointestinal anatomy indicated for an Endoscopic Retrograde Cholangio-Pancreatography (ERCP).

NCT ID: NCT05124795 Terminated - Clinical trials for Metastatic Castration Resistant Prostate Cancer

IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer

Start date: December 9, 2021
Phase: Phase 1
Study type: Interventional

Dose escalation study to evaluate the safety, tolerability and anti-tumor activity of single agent IMU-935 in patients with progressive, metastatic castration resistant prostate cancer (mCRPC).